LT3350223T - Antikūnai, kurie specifiškai rišasi prie tl1a - Google Patents

Antikūnai, kurie specifiškai rišasi prie tl1a

Info

Publication number: LT3350223T
Authority: LT; Lithuania
Prior art keywords: tl1a; antibodies; specifically bind; bind; specifically
Prior art date: 2015-09-18

Application number

LTEP16774750.0T

Other languages

English (en)

Inventor

Lynn Poulton

Matthew Pollard

Anthony Doyle

Bridget Cooksey

Vanya PANDE

Adam CLARKE

Original Assignee

Cephalon, Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-09-18

Filing date

2016-09-16

Publication date

2020-10-26

2016-09-16 Application filed by Cephalon, Inc. filed Critical Cephalon, Inc.

2020-10-26 Publication of LT3350223T publication Critical patent/LT3350223T/lt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pulmonology (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Transplantation (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Sorting Of Articles (AREA)

LTEP16774750.0T 2015-09-18 2016-09-16 Antikūnai, kurie specifiškai rišasi prie tl1a LT3350223T (lt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201562220442P	2015-09-18	2015-09-18
PCT/US2016/052040 WO2017049024A1 (en)	2015-09-18	2016-09-16	Antibodies that specifically bind to tl1a

Publications (1)

Publication Number	Publication Date
LT3350223T true LT3350223T (lt)	2020-10-26

Family

ID=57043002

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LTEP16774750.0T LT3350223T (lt)	2015-09-18	2016-09-16	Antikūnai, kurie specifiškai rišasi prie tl1a

Country Status (33)

Country	Link
US (4)	US10138296B2 (lt)
EP (2)	EP3350223B1 (lt)
JP (2)	JP7013366B2 (lt)
KR (1)	KR101998535B1 (lt)
CN (1)	CN108137693B (lt)
AR (1)	AR106055A1 (lt)
AU (2)	AU2016323460B2 (lt)
BR (2)	BR112018005407A8 (lt)
CA (1)	CA2997015A1 (lt)
CL (1)	CL2018000711A1 (lt)
CO (1)	CO2018003736A2 (lt)
CY (1)	CY1123499T1 (lt)
DK (1)	DK3350223T3 (lt)
EA (1)	EA201890756A1 (lt)
ES (1)	ES2810751T3 (lt)
HR (1)	HRP20201323T1 (lt)
HU (1)	HUE051496T2 (lt)
IL (1)	IL257761B2 (lt)
LT (1)	LT3350223T (lt)
MA (2)	MA42825B1 (lt)
MD (1)	MD3350223T2 (lt)
MX (1)	MX2018003185A (lt)
PE (1)	PE20181080A1 (lt)
PH (1)	PH12018500580B1 (lt)
PL (1)	PL3350223T3 (lt)
PT (1)	PT3350223T (lt)
RS (1)	RS60703B1 (lt)
SI (1)	SI3350223T1 (lt)
SM (1)	SMT202000500T1 (lt)
TW (1)	TWI703158B (lt)
UA (1)	UA125284C2 (lt)
WO (1)	WO2017049024A1 (lt)
ZA (1)	ZA201801427B (lt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20110229471A1 (en)	2008-11-26	2011-09-22	Cedars-Sinai Medical Center	Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease
JP2014531210A (ja)	2011-09-30	2014-11-27	テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド	ＴＬ１ａに対する抗体およびその使用
JP6671276B2 (ja)	2013-03-27	2020-03-25	セダーズ−シナイメディカルセンター	Ｔｌ１ａ機能および関連するシグナル経路の抑制による線維症および炎症の緩和および回復
EP4105236A1 (en)	2013-07-19	2022-12-21	Cedars-Sinai Medical Center	Anti-tl1a (tnfsf15) antibody for treatment of inflammatory bowel disease
TWI703158B (zh) *	2015-09-18	2020-09-01	美商希佛隆公司	特異性結合tl1a之抗體
AU2016364992B2 (en) *	2015-12-04	2021-12-09	University Of Iowa Research Foundation	Apparatus, systems and methods for predicting, screening and monitoring of encephalopathy / delirium
US11186872B2 (en)	2016-03-17	2021-11-30	Cedars-Sinai Medical Center	Methods of diagnosing inflammatory bowel disease through RNASET2
KR20190082815A (ko)	2016-10-26	2019-07-10	세다르스-신나이 메디칼 센터	중화 항-tl1a 단일 클론 항체
CA3061467A1 (en) *	2017-04-28	2019-10-24	Ajinomoto Co., Inc.	Compound having affinity substance to soluble protein, cleavable portionand reactive group, or salt thereof
CN112585165B8 (zh)	2018-04-25	2025-02-14	普罗米修斯生物科学公司	优化的抗tl1a抗体
WO2020232125A1 (en)	2019-05-14	2020-11-19	Prometheus Biosciences, Inc.	Tl1a patient selection methods, systems, and devices
MX2022004942A (es)	2019-10-24	2022-07-27	Prometheus Biosciences Inc	Anticuerpos humanizados contra el ligando 1a de tipo tnf (tl1a) y usos de los mismos.
CN116348481A (zh) *	2020-08-19	2023-06-27	詹森生物科技公司	使用工程化配体的材料和方法
WO2024026395A1 (en)	2022-07-27	2024-02-01	Cephalon Llc	Anti-tl1a antibodies for the treatment of ulcerative colitis and crohn's disease
JP2025526400A (ja)	2022-07-27	2025-08-13	セファロンエルエルシー	抗ｔｌ１ａ抗体製剤
WO2024239006A1 (en)	2023-05-17	2024-11-21	Genentech, Inc.	Anti-tl1a antibody therapeutic methods
WO2024263900A2 (en) *	2023-06-22	2024-12-26	Paragon Therapeutics, Inc.	Il-23 antibody compositions and methods of use
TW202515910A (zh) *	2023-06-22	2025-04-16	美商派拉岡醫療公司	Il-17抗體組合物及使用方法
WO2025038473A1 (en) *	2023-08-11	2025-02-20	Paragon Therapeutics, Inc.	Tl1a binding antibodies and methods of use
US12473370B2 (en)	2023-10-03	2025-11-18	Absci Corporation	TL1A associated antibody compositions and methods of use
CN120058933A (zh) *	2023-11-30	2025-05-30	北京智仁美博生物科技有限公司	抗肿瘤坏死因子样配体1a的抗体及其用途
US20250230251A1 (en)	2023-12-20	2025-07-17	Bristol-Myers Squibb Company	Antibodies targeting il-18 receptor beta (il-18rb) and related methods
CN120424214A (zh) *	2024-02-05	2025-08-05	三生国健药业（上海）股份有限公司	一种抗tl1a抗体及其制备方法和用途
US20250376530A1 (en)	2024-05-17	2025-12-11	Genentech, Inc.	Methods for treatment of inflammatory bowel disease with an anti-tl1a antibody
CN119552252B (zh) *	2025-01-16	2025-11-25	华润生物医药有限公司	抗tl1a抗体及其制备方法和应用

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7597886B2 (en)	1994-11-07	2009-10-06	Human Genome Sciences, Inc.	Tumor necrosis factor-gamma
US7820798B2 (en)	1994-11-07	2010-10-26	Human Genome Sciences, Inc.	Tumor necrosis factor-gamma
KR101077001B1 (ko)	1999-01-15	2011-10-26	제넨테크, 인크.	효과기 기능이 변화된 폴리펩티드 변이체
US6548062B2 (en) *	2000-02-29	2003-04-15	Cephalon, Inc.	Method of treating cancer with anti-neurotrophin agents
DK1355919T3 (da)	2000-12-12	2011-03-14	Medimmune Llc	Molekyler med længere halveringstider, sammensætninger og anvendelser deraf
US7317091B2 (en)	2002-03-01	2008-01-08	Xencor, Inc.	Optimized Fc variants
US20040132101A1 (en)	2002-09-27	2004-07-08	Xencor	Optimized Fc variants and methods for their generation
US7217797B2 (en)	2002-10-15	2007-05-15	Pdl Biopharma, Inc.	Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US20040191243A1 (en)	2002-12-13	2004-09-30	Bei Chen	System and method for stabilizing antibodies with histidine
US20080233119A2 (en)	2003-08-20	2008-09-25	University Of Miami	Compositions and methods for treating inflammatory lung disease
WO2005092927A1 (en)	2004-03-23	2005-10-06	Biogen Idec Ma Inc.	Receptor coupling agents and therapeutic uses thereof
GB0521621D0 (en) *	2005-10-24	2005-11-30	Domantis Ltd	Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases
US20090317388A1 (en)	2005-05-25	2009-12-24	Linda Burkly	Tl1a in treatment of disease
EP1919954B1 (en)	2005-08-30	2016-10-19	University of Miami	Immunomodulating tumor necrosis factor receptor 25 (tnfr25) agonists, antagonists and immunotoxins
WO2007076465A2 (en)	2005-12-23	2007-07-05	Diadexus, Inc.	Cln248 antibody compositions and methods of use
US9068003B2 (en)	2007-01-10	2015-06-30	The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services	Antibodies that bind to TL1A and methods of treating inflammatory or autoimmune disease comprising administering such antibodies
US20110217310A1 (en)	2007-01-10	2011-09-08	Siegel Richard M	Blockade of tl1a-dr3 interactions to ameliorate t cell mediated disease pathology
WO2008106451A2 (en)	2007-02-26	2008-09-04	Cedars-Sinai Medical Center	Methods of using single nucleotide polymorphisms in the tl1a gene to predict or diagnose inflammatory bowel disease
WO2009052512A2 (en)	2007-10-19	2009-04-23	Cedars-Sinai Medical Center	Methods of using genetic variants to diagnose and predict inflammatory bowel disease
US8263743B2 (en)	2007-11-13	2012-09-11	Teva Biopharmaceuticals Usa, Inc.	Humanized antibodies against TL1A
US20120073585A1 (en)	2009-04-08	2012-03-29	Cedars-Sinai Medical Center	Methods of predicting complication and surgery in crohn's disease
WO2011080314A2 (en)	2009-12-31	2011-07-07	Deutsches Krebsforschungszentrum	Novel modulators of trail signalling
JO3375B1 (ar)	2010-11-08	2019-03-13	Regeneron Pharma	أجسام مضادة بشرية للجين a1 الشبيه بعامل النخر الورمي (tl1a)
WO2012174338A2 (en)	2011-06-15	2012-12-20	Glaxosmithkline Llc	Method of selecting therapeutic indications
JP2014531210A (ja)	2011-09-30	2014-11-27	テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド	ＴＬ１ａに対する抗体およびその使用
US9592297B2 (en)	2012-08-31	2017-03-14	Bayer Healthcare Llc	Antibody and protein formulations
JP2016503818A (ja) *	2013-01-02	2016-02-08	グレンマークファーマシューティカルズ，エセ．アー．	Ｔｌ１ａと結合する抗体およびその使用
JP6671276B2 (ja)	2013-03-27	2020-03-25	セダーズ−シナイメディカルセンター	Ｔｌ１ａ機能および関連するシグナル経路の抑制による線維症および炎症の緩和および回復
MX2015013901A (es) *	2013-04-05	2015-12-11	Genentech Inc	Anticuerpos anti-il-4 y anticuerpos biespecificos y sus usos.
WO2014186665A2 (en)	2013-05-17	2014-11-20	Cedars-Sinai Medical Center	Distinct effects of ifn-gamma and il-17 on tl1a modulated inflammation and fibrosis
JP6482533B2 (ja)	2013-05-17	2019-03-13	セダーズ−シナイメディカルセンター	クローン病に関連するｔｎｆｓｆ１５及びｄｃｒ３の変異体
EP4105236A1 (en)	2013-07-19	2022-12-21	Cedars-Sinai Medical Center	Anti-tl1a (tnfsf15) antibody for treatment of inflammatory bowel disease
AU2014317991A1 (en)	2013-09-06	2016-03-10	Cedars-Sinai Medical Center	Systems, devices and methods for anti-TL1A therapy
CA2929784C (en)	2013-11-13	2019-11-26	Pfizer Inc.	Tumor necrosis factor-like ligand 1a specific antibodies and compositions and uses thereof
AU2016248347A1 (en)	2015-04-15	2017-11-30	Biosearch Technologies, Inc.	Dual quencher probes
EP3294336A1 (en)	2015-05-15	2018-03-21	Cedars-Sinai Medical Center	Models, methods and compositions for treating inflammatory bowel disease
CA2994719A1 (en)	2015-08-21	2017-03-02	The Children's Hospital Of Philadelphia	Methods of treating autoimmune conditions in patients with genetic variations in dcr3 or in a dcr3 network gene
TWI703158B (zh)	2015-09-18	2020-09-01	美商希佛隆公司	特異性結合tl1a之抗體
US20180319889A1 (en)	2015-11-02	2018-11-08	La Jolla Institute For Allergy & Immunology	Method and medicament for treating airway and/or lung diseases
CR20180365A (es)	2015-12-16	2018-09-28	Amgen Inc	PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS
US11186872B2 (en)	2016-03-17	2021-11-30	Cedars-Sinai Medical Center	Methods of diagnosing inflammatory bowel disease through RNASET2
US10968279B2 (en)	2016-05-09	2021-04-06	Bristol-Myers Squibb Company	TL1A antibodies and uses thereof
GB201608323D0 (en)	2016-05-12	2016-06-29	Ucb Biopharma Sprl	Pharmaceutical compositions
SG11201810853UA (en)	2016-06-09	2019-01-30	Pelican Therapeutics Inc	Anti-tnfrsf25 antibodies
KR20190082815A (ko)	2016-10-26	2019-07-10	세다르스-신나이 메디칼 센터	중화 항-tl1a 단일 클론 항체
US10626180B2 (en)	2017-04-20	2020-04-21	Cedars-Sinai Medical Center	Methods of treating and predicting non-response to anti-TNF treatment in subjects with inflammatory bowel disease
CN112585165B8 (zh)	2018-04-25	2025-02-14	普罗米修斯生物科学公司	优化的抗tl1a抗体
MA52251A (fr)	2018-04-30	2021-02-17	Cedars Sinai Medical Center	Procédés et systèmes de sélection et de traitement de patients souffrant de maladies inflammatoires
CA3121167A1 (en)	2018-11-29	2020-06-04	Cedars-Sinai Medical Center	Methods of stratifying and treating a sub-population of inflammatory bowel disease patients
WO2020232125A1 (en)	2019-05-14	2020-11-19	Prometheus Biosciences, Inc.	Tl1a patient selection methods, systems, and devices
TWI871367B (zh)	2019-10-24	2025-02-01	美商普羅米修斯生物科學股份有限公司	針對類-tnf配體1a(tl1a)之人類化抗體及其用途
WO2021108694A1 (en)	2019-11-27	2021-06-03	Cedars-Sinai Medical Center	Predicting extraintestinal manifestations of inflammatory bowel disease
EP4162076A4 (en)	2020-06-03	2024-10-02	Cedars-Sinai Medical Center	TREATMENTS FOR A SUBPOPULATION OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE
WO2021247770A1 (en)	2020-06-03	2021-12-09	Cedars-Sinai Medical Center	Methods and systems for measuring post-operative disease recurrence
BR112022025667A2 (pt)	2020-06-26	2023-03-07	Pfizer	Métodos de tratamento da doença inflamatória intestinal com anticorpos tl1a
JP2023551602A (ja)	2020-11-13	2023-12-08	プロメテウスバイオサイエンシーズ，インク．	Ｔｌ１ａを標的とする炎症性疾患の治療のための方法、システム、およびキット
WO2022119842A1 (en)	2020-12-01	2022-06-09	Cedars-Sinai Medical Center	Methods and systems of stratifying inflammatory disease patients
CA3202510A1 (en)	2020-12-21	2022-06-30	Dermot P. Mcgovern	Tl1a therapy compositions and methods of treatment therewith
TW202246322A (zh)	2021-02-18	2022-12-01	美商普羅米修斯生物科學股份有限公司	包含針對類tnf配體1a(tl1a)之人類化抗體之組合物及其用途
CA3207818A1 (en)	2021-02-18	2022-08-25	Allison LUO	Anti-tl1a antibody compositions and methods of treatment in the lung
WO2022232253A1 (en)	2021-04-28	2022-11-03	Cedars-Sinai Medical Center	Patient selection methods and kits for therapies targeting tl1a
WO2023102071A1 (en)	2021-12-01	2023-06-08	Cedars-Sinai Medical Center	Microbial metabolites on intestinal inflammation
WO2023102051A1 (en)	2021-12-01	2023-06-08	Cedars-Sinai Medical Center	Intestinal mononuclear phagocytes as prognostic biomarker for crohn's disease
AR128226A1 (es)	2022-01-07	2024-04-10	Prometheus Biosciences Inc	Métodos para tratar enfermedades inflamatorias con una combinación de inhibidores de tl1a e inhibidores de il23
US20240059799A1 (en)	2022-05-11	2024-02-22	Pfizer Inc.	Anti-tl1a antibodies and methods of use thereof

2016
- 2016-09-14 TW TW105130075A patent/TWI703158B/zh active
- 2016-09-16 BR BR112018005407A patent/BR112018005407A8/pt active IP Right Grant
- 2016-09-16 AU AU2016323460A patent/AU2016323460B2/en active Active
- 2016-09-16 MA MA42825A patent/MA42825B1/fr unknown
- 2016-09-16 HR HRP20201323TT patent/HRP20201323T1/hr unknown
- 2016-09-16 CA CA2997015A patent/CA2997015A1/en active Pending
- 2016-09-16 EA EA201890756A patent/EA201890756A1/ru unknown
- 2016-09-16 PT PT167747500T patent/PT3350223T/pt unknown
- 2016-09-16 PL PL16774750T patent/PL3350223T3/pl unknown
- 2016-09-16 SI SI201630885T patent/SI3350223T1/sl unknown
- 2016-09-16 EP EP16774750.0A patent/EP3350223B1/en active Active
- 2016-09-16 HU HUE16774750A patent/HUE051496T2/hu unknown
- 2016-09-16 RS RS20200983A patent/RS60703B1/sr unknown
- 2016-09-16 MD MDE20180714T patent/MD3350223T2/ro unknown
- 2016-09-16 DK DK16774750.0T patent/DK3350223T3/da active
- 2016-09-16 UA UAA201804192A patent/UA125284C2/uk unknown
- 2016-09-16 BR BR122021002400A patent/BR122021002400A8/pt active Search and Examination
- 2016-09-16 EP EP20151834.7A patent/EP3693393A1/en active Pending
- 2016-09-16 CN CN201680053598.8A patent/CN108137693B/zh active Active
- 2016-09-16 MX MX2018003185A patent/MX2018003185A/es unknown
- 2016-09-16 US US15/267,213 patent/US10138296B2/en active Active
- 2016-09-16 MA MA052643A patent/MA52643A/fr unknown
- 2016-09-16 PH PH1/2018/500580A patent/PH12018500580B1/en unknown
- 2016-09-16 SM SM20200500T patent/SMT202000500T1/it unknown
- 2016-09-16 IL IL257761A patent/IL257761B2/en unknown
- 2016-09-16 WO PCT/US2016/052040 patent/WO2017049024A1/en not_active Ceased
- 2016-09-16 JP JP2018512167A patent/JP7013366B2/ja active Active
- 2016-09-16 LT LTEP16774750.0T patent/LT3350223T/lt unknown
- 2016-09-16 AR ARP160102834A patent/AR106055A1/es unknown
- 2016-09-16 KR KR1020187007337A patent/KR101998535B1/ko active Active
- 2016-09-16 PE PE2018000398A patent/PE20181080A1/es unknown
- 2016-09-16 ES ES16774750T patent/ES2810751T3/es active Active
2018
- 2018-02-28 ZA ZA2018/01427A patent/ZA201801427B/en unknown
- 2018-03-16 CL CL2018000711A patent/CL2018000711A1/es unknown
- 2018-04-09 CO CONC2018/0003736A patent/CO2018003736A2/es unknown
- 2018-10-18 US US16/164,509 patent/US11220549B2/en active Active
2020
- 2020-08-17 CY CY20201100767T patent/CY1123499T1/el unknown
2021
- 2021-11-30 US US17/538,530 patent/US12162946B2/en active Active
2022
- 2022-01-17 JP JP2022005039A patent/JP7341259B2/ja active Active
2023
- 2023-06-01 AU AU2023203440A patent/AU2023203440A1/en active Pending
2024
- 2024-11-06 US US18/939,176 patent/US20250179202A1/en active Pending

Also Published As

Publication number	Publication date
HRP20201323T1 (hr)	2020-11-27
BR122021002400A2 (lt)	2018-10-09
PH12018500580B1 (en)	2023-01-11
AR106055A1 (es)	2017-12-06
CN108137693B (zh)	2021-11-26
HK1251002A1 (en)	2019-01-18
US20220185902A1 (en)	2022-06-16
TWI703158B (zh)	2020-09-01
EP3350223A1 (en)	2018-07-25
JP2018528773A (ja)	2018-10-04
CO2018003736A2 (es)	2018-07-10
MX2018003185A (es)	2018-08-01
KR20180048712A (ko)	2018-05-10
EP3350223B1 (en)	2020-06-17
RS60703B1 (sr)	2020-09-30
PE20181080A1 (es)	2018-07-05
UA125284C2 (uk)	2022-02-16
AU2016323460A1 (en)	2018-03-29
US12162946B2 (en)	2024-12-10
US20190106486A1 (en)	2019-04-11
JP7013366B2 (ja)	2022-02-15
BR122021002400A8 (pt)	2023-01-24
ZA201801427B (en)	2019-06-26
JP2022051771A (ja)	2022-04-01
PH12018500580A1 (en)	2018-10-15
HUE051496T2 (hu)	2021-03-01
AU2023203440A1 (en)	2023-06-29
AU2016323460B2 (en)	2023-06-15
PL3350223T3 (pl)	2021-03-08
US20170081400A1 (en)	2017-03-23
TW201722990A (zh)	2017-07-01
US10138296B2 (en)	2018-11-27
PT3350223T (pt)	2020-08-05
MA42825B1 (fr)	2020-09-30
CL2018000711A1 (es)	2018-11-23
SMT202000500T1 (it)	2020-11-10
HK1256300A1 (zh)	2019-09-20
ES2810751T3 (es)	2021-03-09
BR112018005407A8 (pt)	2023-01-24
IL257761A (en)	2018-04-30
CA2997015A1 (en)	2017-03-23
JP7341259B2 (ja)	2023-09-08
KR101998535B1 (ko)	2019-07-09
WO2017049024A1 (en)	2017-03-23
SI3350223T1 (sl)	2020-10-30
NZ740731A (en)	2024-07-26
EP3693393A1 (en)	2020-08-12
IL257761B (en)	2022-11-01
CY1123499T1 (el)	2022-03-24
MD3350223T2 (ro)	2020-09-30
IL257761B2 (en)	2023-03-01
BR112018005407A2 (en)	2018-10-09
MA52643A (fr)	2021-03-24
EA201890756A1 (ru)	2018-08-31
CN108137693A (zh)	2018-06-08
US11220549B2 (en)	2022-01-11
DK3350223T3 (da)	2020-08-24
US20250179202A1 (en)	2025-06-05

Publication	Publication Date	Title
ZA201801427B (en)	2019-06-26	Antibodies that specifically bind to tl1a
IL285287B1 (en)	2023-03-01	Antibodies to tigit
IL284336B (en)	2022-06-01	Treatment using antibodies that bind to ctla4
IL286807A (en)	2021-10-31	Antibodies to icos
HUS2300036I1 (hu)	2024-07-28	IL-23 kötõ antitestek
IL269226A (en)	2019-11-28	Antibodies that bind to TL1A and uses thereof
IL261188A (en)	2018-10-31	Antibodies against tigit
IL256848A (en)	2018-03-29	Antibody molecules that bind cd45
IL256846A (en)	2018-03-29	antibody molecules that bind cd22
IL269394A (en)	2019-11-28	Antibodies bind to STEAP-1
HUE051165T2 (hu)	2021-03-01	ANG-2 elleni, csak nehézláncot tartalmazó antitestek
GB201609742D0 (en)	2016-07-20	Improvements relating to antibodies
GB201507228D0 (en)	2015-06-10	Antibodies to IL-24